Needham & Company initiates coverage on Cepheid (NASDAQ: CPHD) with a Hold.

Analyst Mike Matson weighs in: "CPHD's GeneXpert ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE